This article compares regular NMN and liposomal NMN from the perspective of delivery efficiency, user experience, and formulation value. Regular NMN remains a practical choice for daily NAD⁺ maintenance, especially when supported by human clinical evidence. Liposomal NMN, however, offers an advanced delivery approach through lipid encapsulation, which may help protect NMN and support more efficient uptake. EffePharm’s LipoAvail® Liposomal NMN, with product data showing a 5.9X NAD⁺ increment in liver tissue, is positioned as a premium option for brands seeking differentiated NAD⁺ booster solutions.